ClotProtect

Executive Summary

ClotProtect is a clinical-stage biopharmaceutical company focused on developing next-generation antithrombotic therapies that aim to prevent dangerous blood clots with significantly reduced bleeding risk compared to current standard-of-care anticoagulants. The company's lead program targets large unmet needs in stroke prevention, deep vein thrombosis, and other thrombotic disorders. Based in London, UK, and having raised undisclosed funding, ClotProtect has advanced its lead candidate into Phase 2 clinical trials, positioning itself to address the critical safety limitations of existing treatments that often force trade-offs between efficacy and bleeding complications. ClotProtect's novel approach leverages a differentiated mechanism designed to achieve potent anticoagulation while preserving hemostatic function, potentially broadening the eligible patient population and improving compliance. With a streamlined Phase 2 design and a strong scientific foundation, the company is well-positioned to generate pivotal data within the next 12-18 months. If successful, ClotProtect could capture significant market share in the multi-billion-dollar anticoagulant market, which is currently dominated by drugs like apixaban and rivaroxaban but remains underserved for high-bleeding-risk patients. The upcoming data readout represents a key inflection point for the company, with potential for strategic partnerships or further financing to support Phase 3 development.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Top-Line Data Readout35% success
• Q1 2027FDA/EMA Meeting to Align on Phase 3 Design70% success
• H2 2026Partnership or Licensing Deal for Lead Candidate40% success